08.02.2022 - abc biopply last year’s revenues up more than twice in its strategic core business
The extraordinary market success of the 3D CoSeedis™ technology confirms a trend in the field of drug discovery that calls for new and more native 3D models, to better predict later clinical success of preclinically active compounds. The 3D CoSeedis™ Preclinical Models fulfill these requirements in an exemplary way and at the same time help the customers to reduce time and financial expenses at the earliest stage possible. The company attributes its extraordinary success in part to the increased need for outsourcing last year due to the ongoing pandemic and the associated work restrictions, including at major international customers. abc biopply offers its 3D CoSeedis™ assay portfolio as a CRO service or licenses the 3D models to its customers for in-house use.
The company has developed its proprietary 3D CoSeedis™ platform, a 3D technology especially designed to speed up drug discovery processes and to make preclinical studies faster and more predictive. Leading pharmaceutical companies worldwide already rely on the validated assay portfolio. Using the 3D CoSeedis™ assays they’re analyzing important parameters such as pharmacology, pharmacokinetics, toxicology, etc. fast and cost efficient and, most importantly, under native conditions. Because the model generates hundreds of identical spheroids per measured data point in one step it provides unique predictiveness and consequently reduces the use of animals to a minimum. The 3D CoSeedis™ Preclinical Study Cycle has originally been developed for solid tumors. However the company is currently validating the 3D model also for various neurological applications.
For the year 2022, abc biopply expects a further expansion of its market success. The demand for the services offered continues unchanged and numerous new project contracts are about to be signed.